|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104530 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-18 15:45:26 |
|
注册时间: Date of Registration: |
2025-06-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
超微血流成像技术对乳腺良恶性肿瘤的诊断价值研究 |
|
Public title: |
A study on the diagnostic value of ultramicrofluidic imaging for distinguishing between benign and malignant breast tumours |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
超微血流成像技术对乳腺良恶性肿瘤的诊断价值研究 |
|
Scientific title: |
A study on the diagnostic value of ultramicrofluidic imaging for distinguishing between benign and malignant breast tumours |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林腾 |
研究负责人: |
林腾 |
|
Applicant: |
Lin Teng |
Study leader: |
Lin Teng |
|
申请注册联系人电话: Applicant telephone: |
+86 13502952420 |
研究负责人电话:
Study leader's |
+86 754 88905199 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13502952420@163.com |
研究负责人电子邮件: Study leader's E-mail: |
13502952420@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省汕头市金平区长平路57号 |
研究负责人通讯地址: |
广东省汕头市金平区长平路57号 |
|
Applicant address: |
No. 57, Changping Road, Jinping District, Shantou City, Guangdong Province |
Study leader's address: |
No. 57, Changping Road, Jinping District, Shantou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
汕头大学医学院第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Shantou University Medical College |
||
|
研究负责人所在单位: |
汕头大学医学院第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Shantou University Medical College |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
汕大医附一伦审第B-2025-62号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
汕头大学医学院第一附属医院临床科研伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of First Affiliated Hospital of Shantou University Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-20 00:00:00 | ||
|
伦理委员会联系人: |
林宇洵 |
||
|
Contact Name of the ethic committee: |
Lin Yuxun |
||
|
伦理委员会联系地址: |
广东省汕头市金平区长平路57号 |
||
|
Contact Address of the ethic committee: |
No. 57, Changping Road, Jinping District, Shantou City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 754 88905647 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
sdfyllwyh@163.com |
|
研究实施负责(组长)单位: |
汕头大学医学院第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
the First Affiliated Hospital of Shan Tou University Medical College |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省汕头市金平区长平路57号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 57, Changping Road, Jinping District, Shantou City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
深圳迈瑞生物医疗电子股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shenzhen Mindray Biomedical Electronics Co. |
||||||||||||||||||||||
|
研究疾病: |
超声诊断为ACR BI-RADS 3-5类的乳腺结节 |
||||||||||||||||||||||
|
Target disease: |
Breast nodule diagnosed by ultrasound as ACR BI-RADS category 3-5 |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
主要研究目的:通过应用超微血流成像(UMA)技术,对乳腺良恶性结节进行评估,以明确肿瘤内微血管形态特征在评估乳腺良恶性结节中的应用价值。 次要研究目的:评估常规超声联合超微血流成像能否提高乳腺癌诊断敏感性和特异性,调整乳腺结节BI-RADS 的分类级别,以减少结节不必要的活检,提高穿刺活检阳性率,另外,通过评估肿瘤内微血管形态特征预测淋巴结转移结局。 |
||||||||||||||||||||||
|
Objectives of Study: |
The primary research objective is to evaluate benign and malignant breast nodules by applying ultramicrohaematography (UMA) technology. This will allow clarification of the application value of intra-tumour microvascular morphologic features in the assessment of benign and malignant breast nodules. The secondary research objectives are threefold: firstly, to assess whether conventional ultrasound combined with ultrasound microfluidic imaging can improve the diagnostic sensitivity and specificity of breast cancer; secondly, to adjust the classification level of BI-RADS for breast nodules in order to reduce unnecessary biopsy of the nodules and to improve the positive rate of penetrating biopsy; and thirdly, to predict the outcome of lymph node metastasis through the assessment of intra-tumour microvascular morphology features. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.超声诊断为ACR BI-RADS 3-5类乳腺结节的患者; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients with an ultrasound diagnosis of an ACR BI-RADS category 3-5 breast nodule; |
||||||||||||||||||||||
|
排除标准: |
1.两年内接受过同侧乳腺放射治疗、化学治疗或手术切除;无法配合完成超声检查或病理诊断; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.The patient has undergone one or more of the following treatments: radiation therapy, chemotherapy, or surgical removal of the ipsilateral breast within a two-year period. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-20 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-20 00:00:00 至 To 2026-12-31 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:由两名高年资超声医师独立评估结节形态学及血流参数。数据存储:使用电子数据采集表记录数据,包含患者基线信息(年龄、绝经状态)、超声参数(形态学特征、UMA指标)、病理结果(良恶性、淋巴结转移状态)。数据匿名化处理:患者信息以唯一编码替代(如UMA-001),编码表加密存储于独立服务器。超声图像及病理报告去除所有身份标识(姓名、身份证号) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The process of acquiring data. The assessment of nodal morphology and blood flow parameters was conducted by two senior ultrasonographers, who were not involved in the patient's care. The following section will address the matter of data storage. The data were recorded using an electronic data capture form containing baseline patient information (age, menopausal status), ultrasound parameters (morphological features, UMA indicators), and pathological findings (benign and malignant, lymph node metastatic status). The process of data anonymisation involves the replacement of patient information with a unique code (e.g. UMA-001). The code list is then encrypted and stored on a separate server. The removal of identifiers such as names and ID numbers is a prerequisite for the use of ultrasound images and pathology reports. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |